Abstract
Small cell lung cancer (SCLC) is an aggressive malignancy representing 15% of lung cancers. Approximately 2/3 of patients are diagnosed with extensive stage (ES) disease. Initial treatment involves platinum-based chemotherapy, with recent evidence supporting the addition of immunotherapy, followed in some cases by thoracic radiotherapy and/or prophylactic cranial irradiation (PCI). Despite high response rates to initial therapy, relapses are common and overall survival is poor. There is limited prospective evidence to guide 2nd line systemic therapy and beyond.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
